PatientsVille.com Logo

PANCYTOPENIA and OMEPRAZOLE

PatientsVille

PANCYTOPENIA Symptoms and Causes

If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body.

Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction.

Conditions that may lead to anemia include

  • Heavy periods
  • Pregnancy
  • Ulcers
  • Colon polyps or colon cancer
  • Inherited disorders
  • A diet that does not have enough iron, folic acid or vitamin B12
  • Blood disorders such as sickle cell anemia and thalassemia, or cancer
  • Aplastic anemia, a condition that can be inherited or acquired
  • G6PD deficiency, a metabolic disorder

Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache.

Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for PANCYTOPENIA

PANCYTOPENIA treatment research studies

OMEPRAZOLE clinical trials, surveys and public health registries


Find Drug Side Effect reports



OMEPRAZOLE Side Effects

Hypomagnesaemia (418)
Diarrhoea (311)
Hypocalcaemia (288)
Nausea (285)
Renal Failure Acute (241)
Vomiting (240)
Dyspnoea (225)
Dizziness (205)
Gastrooesophageal Reflux Disease (191)
Fatigue (168)
Pain (164)
Abdominal Pain (163)
Headache (157)
Malaise (155)
Dyspepsia (152)
Rash (148)
Asthenia (146)
Fall (137)
Abdominal Pain Upper (133)
Confusional State (130)
Hypokalaemia (126)
Condition Aggravated (125)
Pruritus (120)
Arthralgia (118)
Anxiety (117)
Tubulointerstitial Nephritis (116)
Pyrexia (116)
Hyponatraemia (115)
Product Substitution Issue (113)
Paraesthesia (112)
Weight Decreased (111)
Muscle Spasms (109)
Anaemia (106)
Decreased Appetite (104)
Chest Pain (100)
Dysphagia (93)
Convulsion (88)
Dehydration (86)
Depression (84)
Cough (84)
Lethargy (79)
Urticaria (78)
Constipation (78)
Muscular Weakness (78)
Pain In Extremity (76)
Myalgia (76)
Tetany (73)
Tremor (73)
Oedema Peripheral (73)
Pneumonia (72)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I started taken omeprazole. I ran out of my Nexum well I started itching really bad as it I had bug bites believe me I will never uses this again. I've never had reaction to a med before

I stopped taking Omeprazole 20mg after 4 days because of a side effect, strong palpitations most of the time; I stopped taking them a week ago and still have the palpitations. It's very scary........

I am experiencing itching on my arms, rashes on arms and shoulders, hoarseness, slight dizziness, trouble sleeping and mild headaches. I was prescribed this medication for treatment of bloating caused by my hiatal hernia but can

After 2 weeks skin burning on chest and back nevrous sytoms O:-) :'(

After the 1st week I suffered from severe dizzyness, nausea and headaches. Vomited everything I ate. Yet around 5pm I would always feel relatively human again.

An update, It has only been 3 days & my arm pain has gone!!, for anybody suffering similar symptoms to mine this is what i done...1.STOP taking omeprazole. 2. buy plenty bottled water & drink upto 6 bottles per day. 3 eat healthy (det

Been taking omeprazole for 6 years. during that time diagnosed with osteoporsis. after reading about this seems any proton pump inhibitor can cause. so angry with doctor. looking now for new drug, severe gerd and hiatal hernia.

Both arms , upper arm muscle weakness and pain, , dosage 40mg twice a day

By day 4 severe leg pain, joing pain and cramping and prior never had this pain. All my muscles appear to be tighting up and going to discontinue this ASAP. I guess I am having a very rare reation to Prilosec.

Could the omeprazole be causing sking irritation and the spots that have appeared in my scalp, i was much better when i was taking lanzoperazole

PANCYTOPENIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Fanconi's Anemia;   Anemia, Diamond Blackfan;   Dyskeratosis Congenital;   Thrombocytopenia;   Neutropenia
Intervention:
Outcome Measure:
2 Recruiting CD34+ Stem Cell Infusion to Augment Graft Function
Conditions: Waning Donor Chimerism;   Waning Immune Function;   Primary Immunodeficiency Disease(s);   Bone Marrow Failure
Intervention: Biological: CD34+
Outcome Measures: Augmentation of graft function;   Frequency and characteristics of potential infusion-related toxicity
3 Recruiting Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Outcome Measures: Donor cell engraftment;   Regimen-related toxicities as assessed by NCI's Common Toxicity Criteria;   Acute and chronic GVHD;   overall survival;   event-free survival
4 Recruiting Evaluation, Treatment, and Training for Patients With Blood Disorders
Conditions: Hematologic Disease;   Hematologic Neoplasm;   Pancytopenia
Intervention:
Outcome Measure:
5 Recruiting Nandrolone Decanoate in the Treatment of Telomeropathies
Conditions: Aplastic Anemia;   Bone Marrow Failure Syndromes;   Idiopathic Pulmonary Fibrosis;   Telomere Shortening
Intervention: Drug: Nandrolone Decanoate
Outcome Measures: Reduction in telomere attrition;   Hematologic response;   Clonal evolution;   Improvement in lung function;   Survival;   Safety
6 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
Outcome Measure:
7 Recruiting G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
Condition: Hematologic Malignancies
Intervention: Drug: Granulocyte Colony Stimulating Factor
Outcome Measures: To examine the engraftment rate in patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donor.;   To evaluate the incidence and severity of acute and chronic graft-versus-host disease in patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donor.
8 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
Outcome Measures: Primary endpoint of this study is chronic GVHD by one year.;   Transplant related mortality, engraftment, degree of donor-host chimerism, incidence of acute and chronic graft versus host disease (GVHD), transplant related morbidity and overall survival.
9 Unknown  Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Conditions: Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30
Outcome Measures: This study is to determine the toxicity of administering a fludarabine/cyclophosphamide (Flu/CY) or busulfan (Bu)/Flu based conditioning regimen followed by allogeneic stem cell transplant.;   To determine the risk of disease progression (including neuropsychological deterioration in patients with metabolic non-malignant diseases) following a Flu/CY or Bu/Flu based conditioning regimen.;   To measure immune reconstitution following a Flu/CY or Bu/Flu based conditioning regimen and AlloSCT in patients with selected non-malignant diseases.;   To estimate the incidence and severity of GVHD following a Flu/Cy or Bu/Flu based conditioning regimen;   To determine metabolic/immune (gene/protein) reconstitution by standard biochemical/PCR assays in patients
10 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CliniMacs (PLUS) Reagent System
Outcome Measures: Incidence of acute graft versus host disease (GVHD);   Incidence of primary graft failure;   Survival Rate;   Time to neutrophil and platelet engraftment;   Time to immune reconstitution;   Incidence of infectious complications;   Incidence of secondary graft failure
11 Recruiting Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
Interventions: Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
Outcome Measures: Day +100 Post-transplant Survival;   Primary engraftment;   Secondary graft failure;   Regimen-related toxicity;   Acute and chronic graft-versus-host disease (GVHD);   Viral reactivation and infection;   Peripheral blood neutrophil and T cell chimerism;   Pulmonary function;   Long-term overall survival;   Malignancies
12 Recruiting Screening for Hematology Branch Protocols
Conditions: Anemia;   Hematologic Neoplasm;   Neutropenia;   Pancytopenia;   Thrombocytopenia
Intervention:
Outcome Measure: Determine patient eligibility
13 Recruiting Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Conditions: Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
Outcome Measures: The primary endpoint will be the rate of complete hematologic response at six months.;   Secondary endpoints are relapse, robust hematologic blood count recovery at 3, 6, and 12 months, survival, clonal evolution to myelodysplasia and leukemia, and marrow stem cell content.
14 Recruiting Sirolimus for Autoimmune Disease of Blood Cells
Conditions: Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
Intervention: Drug: sirolimus
Outcome Measures: To define the toxicities of administration of oral sirolimus in children with autoimmune cytopenias;   To evaluate the efficacy of oral sirolimus in children with autoimmune cytopenias;   To characterize the trough levels produced by administration of oral sirolimus in children with autoimmune cytopenias;   To evaluate the effect of sirolimus on intracellular targets
15 Recruiting Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia
Condition: Aplastic Anemia
Intervention: Drug: ATG-fresenius
Outcome Measures: absolute blood counts not meeting the criteria of Aplastic Anemia;   transfusion dependency after ATG treatment;   sustained improvement of blood counts post ATG;   short-term safety of ATG and clonal evolution;   response rates of ATG treatment
16 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Outcome Measure:
17 Recruiting CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
Interventions: Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
Outcome Measures: To determine the safety, toxicity and feasibility of CD34+ stem cell selection in children, adolescents and young adults receiving a partially matched family or matched unrelated adult donor allogeneic stem cell transplant;   To determine the time to immune reconstitution (T, B, DC) following CD34+ selection in children, adolescents and young adults receiving a partially matched family or matched unrelated adult donor allogeneic stem cell transplant;   To establish the incidence of post transplant lymphoproliferative syndrome, (PTLD) following CD34+ selection in children, adolescents and young adults receiving a partially matched family or matched unrelated adult donor allogeneic stem cell transplant.
18 Recruiting T-cell Depleted Alternative Donor Transplantation
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis
Intervention: Device: CliniMACS® (T cell depletion)
Outcome Measures: Determine rate of severe GVHD.;   Evaluate the rate of engraftment;   Evaluate post-transplant infections;   Evaluate rate of EBV-related post transplant lymphoproliferative disorder (PTLD);   Evaluate post-transplant leukemia relapse;   Evaluate transplant-related mortality;   Evaluate transplant-related toxicities;   Evaluate overall survival;   Monitor device performance: purity of selected product, yield of CD34+ cells, CD3+ cell depletion, viability and sterility.
19 Recruiting Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Conditions: Hematological Malignancy;   Bone Marrow Failure Syndrome
Intervention: Drug: Eltrombopag
Outcome Measures: Platelet engraftment rate up to 50 days post transplantation, defined as the first of 7 consecutive days of an unsupported platelet count of at least 20,000/microliter.;   Time to partial platelet engraftment, defined as the first of 7 consecutive days of an unsupported platelet count of at least 20,000/microliter.;   Time to sustained complete platelet engraftment defined as the first of 7 consecutive days of an unsupported platelet count of at least 50,000/microliter.;   Complete platelet engraftment rates up to 50 days post transplantation defined as the first of 7 consecutive days of an unsupported platelet count of at least 50,000/microliter.;   Time to neutrophil engraftment defined as the first of 3 consecutive days to achieve an absolute neutrophil count ≥ 500/microliter.
20 Not yet recruiting Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Conditions: Multiple Myeloma;   Bone Marrow Failure Syndromes;   Hemoglobinopathies;   AML;   ALL;   Myeloid Leukemia, Chronic;   NHL;   HL;   MDS;   Amyloidosis;   Myelofibrosis
Interventions: Drug: Tacrolimus;   Drug: Anti-thymocyte globulin;   Procedure: Kidney transplant;   Drug: Bone marrow transplant from a related donor;   Radiation: Total body irradiation 400 centigray (200 cGy X 2)
Outcome Measures: The primary endpoint is the renal allograft rejection rate at 6 months post-transplant.;   Assess anti-tumor response rates in patients with hematologic malignancies